Sampat Aluminium IPO allotment likely today: Check latest GMP, step-by-step guide on how to check allotment status


Sampat Aluminum IPO Allotment: After a heavy bidding round on the Indian stock market, investors looking for the SME firm, Sampat Aluminium Ltd, have now turned their attention to the share allotment of the public issue, which is expected on Monday, 22 September 2025.

Stock market investors can check the status of the Sampat Aluminium IPO allotment online through the official portal of the IPO registrar, Cameo Corporate Services, or on the official Bombay Stock Exchange (BSE) website.

Investors can follow the steps below to check the status online on the BSE and the registrar’s website.

Sampat Aluminium IPO allotment status on BSE

Step 1: Visit the allotment page on the official BSE website to check the online status for the Sampat Aluminium IPO allotment.

Direct Link Here — https://www.bseindia.com/investors/appli_check.aspx

Step 2: Select the ‘Equity’ option from the two listed options under the ‘Issue Type’ category.

Step 3: Select ‘Sampat Aluminium Ltd’ IPO from the options displayed under the ‘Issue Name’ category.

Step 4: Enter your Application Number for the public issue or your PAN ID.

Step 5: Select the ‘I am not a Robot’ option to verify your identity, then click on the ‘Submit’ button.

Sampat Aluminium IPO allotment status on Cameo Corporate Services

Step 1: To check the official share allotment status of the Sampat Aluminium IPO at the registrar, Cameo Corporate Services’ website, you have to visit the following link.

Direct Link Here — https://ipostatus2.cameoindia.com/

Step 2: Select the ‘Sampat Aluminium IPO’ from the dropdown list. The name of the public issue will be available once the allocation process is completed.

Step 3: To check your IPO allotment status, you have to select your “Type” of identification, like Application Number, PAN ID, or DP ID – Client ID, for verification.

Step 4: After selecting the “Type” of identification, you have to enter either your Application Number, PAN ID, or DP ID – Client ID.

Step 5: After successfully selecting the “Type” of identification, you have to enter the number of whichever type was selected. Like either Application Number, PAN ID, or DP ID.

Step 6: After entering all the necessary details, you have to enter the security Captcha and click on the “Submit” icon.

After following all five steps, your Sampat Aluminium IPO share allotment status will be visible on the screen.

SAMPAT ALUMINUM IPO LATEST GMP

As of Monday, 22 September 2025, the grey market premium (GMP) of Sampat Aluminium IPO stood at 19 per share. With the upper price band for the public issue at 120, the company shares are expected to be listed at 139 apiece, marking a premium of 15.83%, according to Investorgain data.

Grey market premium (GMP) is an investor’s willingness to pay more for a public issue. The IPO’s GMP jumped to its current level of 19 per share, from its previous 13 per share levels on the allotment day.

Sampat Aluminum IPO Details

Sampat Aluminium IPO was offering a book-built public issue comprising a fresh issuance of 25.44 lakh equity shares as the firm aimed to raised 30.53 crore from the Indian stock market via the IPO round. However, there was no offer for sale (OFS) component in the public issue.

The company plans to use 23.3 crore of the proceeds raised from the IPO round to fund its new manufacturing facility in Mehsana, Gujarat, while the remaining amount will be allocated for general corporate purposes.

Sampat Aluminium fixed the IPO’s price band at 114 to 120 per equity share, with a lot size of 1,200 shares per lot. The public issue is expected to be listed on Wednesday, 24 September 2025, at the BSE SME Index.

Marwadi Chandarana Intermediaries Brokers is the book runner of the public issue while, Cameo Corporate Services acts as the registrar to the offer.

Read all stories by Anubhav mukherjee

Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.


Related Posts

Dividend, bonus issue, stock split: Canara Robeco to trade ex-dividend, GRM Overseas ex-bonus issue next week — List

Dividend, bonus issue, stock split: From the interim dividend issue of Canara Robeco and Prakash Pipes, to the bonus issue of GRM Overseas, and the stock split of Knowledge Marine…

Not Bitcoin or Ethereum – These 5 are the top best performing cryptos in 2025

From bitcoin reaching record high of $1,00,000 to retracing around $86,000 level -the crypto market has remained dynamic and volatile so far this year. As of December 2025, the overall…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nearly 700 pages of Jeffrey Epstein documents released by US Justice Department are redacted | World News

  • By admin
  • December 21, 2025
  • 0 views
Nearly 700 pages of Jeffrey Epstein documents released by US Justice Department are redacted | World News

ODI world champs India women back to play Sri Lanka T20Is

  • By admin
  • December 21, 2025
  • 0 views
ODI world champs India women back to play Sri Lanka T20Is

Bowen Yang to depart SNL mid-season, last episode with buddy Ariana Grande

  • By admin
  • December 21, 2025
  • 0 views
Bowen Yang to depart SNL mid-season, last episode with buddy Ariana Grande

Akshaye Khanna’s father Vinod Khanna was Osho’s gardener in the ashram: ‘He lived in a 4×6 room’ | Bollywood News

  • By admin
  • December 21, 2025
  • 0 views
Akshaye Khanna’s father Vinod Khanna was Osho’s gardener in the ashram: ‘He lived in a 4×6 room’ | Bollywood News

Why wired headphones are quietly making sense again | Technology News

  • By admin
  • December 21, 2025
  • 0 views
Why wired headphones are quietly making sense again | Technology News

Nine pharma companies ink deals with Trump to lower drug prices

  • By admin
  • December 21, 2025
  • 3 views
Nine pharma companies ink deals with Trump to lower drug prices